NCT02994498View on ClinicalTrials.gov

Safety and Efficacy of DCB-BO1301 in Advanced Melanoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Melanoma
Interventions
DRUG

DCB-BO1301

1, 2, or 3 capsules, three times a day, oral, at most 48 weeks

All Listed Sponsors
lead

Chung Mei Biopharma Co., Ltd

INDUSTRY

NCT02994498 - Safety and Efficacy of DCB-BO1301 in Advanced Melanoma | Biotech Hunter | Biotech Hunter